Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19
- PMID: 33139895
- PMCID: PMC7604917
- DOI: 10.1038/s41571-020-00448-y
Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19
Abstract
Randomized controlled trials designed to test cancer therapies often fail to clarify effectiveness in real-world settings. Herein, we explore lessons for trial development in oncology that can be learnt from the large-cohort, pragmatic RECOVERY trial involving patients hospitalized with COVID-19.
Conflict of interest statement
V.P. has acted as a consultant of UnitedHealthcare, has received research funding from Arnold Ventures, has received royalties from Johns Hopkins Press and Medscape, has received speaker’s fees from Evicore and for Grand Rounds/lectures from various universities, medical centres, non-profit organizations, and professional societies and has received financial support for the Plenary Session series of podcasts via Patreon. R.B. declares no competing interests.
Comment on
-
Dexamethasone in Hospitalized Patients with Covid-19.N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17. N Engl J Med. 2021. PMID: 32678530 Free PMC article. Clinical Trial.
References
-
- Group RC, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2021436. - DOI
-
- Singh H, et al. FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the U.S. Food and Drug Administration. J. Clin. Oncol. 2017;35(suppl. 15):10009. doi: 10.1200/JCO.2017.35.15_suppl.10009. - DOI